Bowman, Diana M.; Hodge, Graeme A. A big regulatory tool-box for a small technology. NanoEthics 2008 August; 2(2): 193-207. NRCBL: 5.4; 5.2; 5.3. SC: rv.

Brownsword, Roger. Regulating nanomedicine — the smallest of our concerns? NanoEthics 2008 April; 2(1): 73-86. NRCBL: 5.4; 5.3; 4.5; 5.2; 8.3.1.

Cameron, Nigel M. de S. Nanotechnology and the human future: policy, ethics, and risk. Annals of the New York Academy of Sciences 2006 December; 1093: 280-300. NRCBL: 5.4; 4.5; 5.2; 15.1; 1.3.11.

Culliton, Barbara J. Is special FDA regulation of nanomedicine needed? A conversation with Norris E. Alderson [interview]. Health Affairs 2008 March-June; 27(3-4): w315-w317. NRCBL: 5.4; 9.7; 5.3.


Keywords: *nanotechnology; *public health; *risks and benefits; biomedical enhancement; brain; dehumanization; ecology; epidemiology; ethical analysis; genetic engineering; genetic information; genetic screening; health hazards; in vitro fertilization; mass screening; newborns; parental consent; patient care; population genetics; property rights; Proposed Keywords: clinical utility

Evers, Johan; Aerts, Stefan; De Tavernier, Johan. An ethical argument in favor of nano-enabled diagnostics in livestock disease control. NanoEthics 2008 August; 2(2): 163-178. NRCBL: 5.4; 22.3; 1.1.


Glenn, Linda MacDonald; Boyce, Jeannann S. Nanotechnology: considering the complex ethical, legal, and societal issues with the parameters of human performance. Nanoethics 2008 December; 2(3): 265-275. NRCBL: 5.4; 4.5; 5.3.


Joly, Pierre-Benoit; Kaufmann, Alain. Lost in translation? The need for ‘upstream engagement’ with nanotechnology on trial. Science as Culture 2008 September; 17(3): 225-247. NRCBL: 5.4; 15.1; 1.3.11; 5.2; 5.3; 7.1. SC: le.


Kuzma, Jennifer; Besley, John C. Ethics of risk analysis and regulatory review: from bio- to nanotechnology. NanoEthics 2008 August; 2(2): 149-162. NRCBL: 5.4; 5.3; 5.2; 15.1; 1.3.11. SC: rv.

Laurent, Louis; Petit, Jean-Claude. Nanosciences and their convergence with other technologies: new golden age